Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -2.86% 17.00 16.50 17.50 17.00 17.00 17.00 108,533 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.1 -4.4 - 42

Futura Medical PLC Block listing Interim Review - Replacement

10/07/2020 4:31pm

UK Regulatory (RNS & others)


Futura Medical (LSE:FUM)
Historical Stock Chart


From Jul 2020 to Aug 2020

Click Here for more Futura Medical Charts.

TIDMFUM

RNS Number : 7202S

Futura Medical PLC

10 July 2020

The following amendments have been made to the 'Block listing Interim Review' announcement released on 01 June 2020 at 07:00 under RNS No 3808O.

The "Balance of unallotted securities under scheme(s) from previous return" and "Balance under scheme(s) not yet issued/allotted at end of period" have each been amended from 6,225,000 to 9,306,779.

All other details remain unchanged. The full amended text is shown below.

The reason for this change is because the balance of unallotted securities under the block admission was historically incorrectly reduced for lapsed options.

The Company's total issued share capital remains unchanged at 245,626,926 Ordinary Shares.

-------------------------------------------------------------------

Block Listing Six Monthly Return

1 June 2020

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

Date: 1 June 2020

 
 Name of applicant:                                                             Futura Medical Plc 
 Name of scheme:                                                                Unapproved Share Option Scheme 
                                                                                 Unapproved Share Incentive Scheme 
                                                                                 EMI Share Option Scheme 
                                                                               --------------------------------------- 
 Period of return:                                    From:                     1 December 2019     To:   31 May 2020 
                                                     ------------------------  ------------------  ----  ------------- 
 Balance of unallotted securities under scheme(s) from previous return:         9,306,779 
                                                                               --------------------------------------- 
 Plus: The amount by which the block scheme(s) has been increased since the     n/a 
 date of the last 
 return (if any increase has been applied for): 
                                                                               --------------------------------------- 
 Less: Number of securities issued/allotted under scheme(s) during period:      n/a 
                                                                               --------------------------------------- 
 Equals: Balance under scheme(s) not yet issued/allotted at end of period:      9,306,779 
                                                                               --------------------------------------- 
 Number and class of securities originally admitted and the date of admission   USOS Total: 3,882,912 
                                                                                 814,424 25 May 2011 
                                                                                 1,202,280 8 October 2013 
                                                                                 1,466,208 25 May 2017 
                                                                                 400,000 30 May 2018 
                                                                                 USIS Total: 425,000 
                                                                                 425,000 30 November 2018 
                                                                                 EMI Total: 7,012,088 
                                                                                 1,520,576 25 May 2011 
                                                                                 1,467,720 8 October 2013 
                                                                                 1,893,792 25 May 2017 
                                                                                 790,000 30 May 2018 
                                                                                 1,340,000 30 November 2018 
                                                                               --------------------------------------- 
 
 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:

Liberum

Bidhi Bhoma/ Euan Brown

Tel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Supriya Mathur

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 922 0891

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) technology. Each DermaSys(R) formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BLRRMMITMTABBPM

(END) Dow Jones Newswires

July 10, 2020 11:31 ET (15:31 GMT)

1 Year Futura Medical Chart

1 Year Futura Medical Chart

1 Month Futura Medical Chart

1 Month Futura Medical Chart
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200809 08:31:38